Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.

MLA

Uemura, Motohide, et al. “Avelumab plus Axitinib vs Sunitinib for Advanced Renal Cell Carcinoma: Japanese Subgroup Analysis from JAVELIN Renal 101.” Cancer Science, vol. 111, no. 3, Mar. 2020, pp. 907–23. EBSCOhost, https://doi.org/10.1111/cas.14294.

APA

Uemura, M., Tomita, Y., Miyake, H., Hatakeyama, S., Kanayama, H.-O., Numakura, K., Takagi, T., Kato, T., Eto, M., Obara, W., Uemura, H., Choueiri, T. K., Motzer, R. J., Fujii, Y., Kamei, Y., Umeyama, Y., di Pietro, A., & Oya, M. (2020). Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Cancer Science, 111(3), 907–923. https://doi.org/10.1111/cas.14294

Chicago

Uemura, Motohide, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro-Omi Kanayama, Kazuyuki Numakura, Toshio Takagi, et al. 2020. “Avelumab plus Axitinib vs Sunitinib for Advanced Renal Cell Carcinoma: Japanese Subgroup Analysis from JAVELIN Renal 101.” Cancer Science 111 (3): 907–23. doi:10.1111/cas.14294.